Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1569-8041
    Keywords: Integroup trials ; international collaboration ; ovarian cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The rather slow evolution of so-called "optimal chemotherapy" for ovarian cancer is the result of suboptimal randomised clinical trials, not having the statistical power to identify truly superior regimens, and of the lack of systematic comparisons of new agents with relevant control arms. There is little doubt that we need international collaboration to move the field forward in a timely and coherent manner. European and transatlantic collaboration represents the beginning of the process and point to the success that can await us if the drive to work together remains strong. A similar organisation as for breast cancer (Breast International Group, BIG) needs to be established for ovarian cancer.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1569-8041
    Keywords: adjuvant chemotherapy ; DNA ploidy ; early ovarian cancer ; intergroup prospective trials
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Purpose:Adjuvant chemotherapy versus observation and chemotherapyat progression was evaluated in 162 patients in a prospective randomizedmulticenter study. We also evaluated DNA-measurements as an additionalprognostic factor. Patients and methods:Patients received adjuvant carboplatin AUC7 every 28 days for six courses (n = 81) or no adjuvant treatment(n = 81). Eligibility included surgically staged and treated patientswith FIGO stage I disease, grade 1 aneuploid or grade 2 or 3 non-clear cellcarcinomas or clear cell carcinomas. Disease-free (DFS) and disease-specific(DSS) survival were end-points. Results:Median follow-up time was 46 months and progression wasobserved in 20 patients in the treatment group and 19 in the control group.Estimated five-year DFS and DSS were 70% and 86% in thetreatment group and 71% and 85% in the control group. The hazardratio was 0.98 (95% confidence interval (95% CI):0.52–1.83) regarding DFS and 0.94 (95% CI: 0.37–2.36)regarding DSS. No significant differences in DFS or DSS could be seen when thelog-rank test was stratified for prognostic variables. Therefore, data fromboth groups were pooled for the analysis of prognostic factors. DNA-ploidy(P = 0.003), extracapsular growth (P = 0.005), tumor rupture(P = 0.04), and WHO histologic grade (P = 0.04) weresignificant independent prognostic factors for DFS withP 〈 0.0001for the model in the multivariate Cox analysis. FIGO substage (P =0.01), DNA ploidy (P 〈 0.05), and histologic grade (P =0.05) were prognostic for DSS with a P-value for the model 〈0.0001. Conclusions:Due to the small number of patients the study wasinconclusive as regards the question of adjuvant chemotherapy. The survivalcurves were superimposable, but with wide confidence intervals. DNA-ploidyadds objective independent prognostic information regarding both DFS and DSSin early ovarian cancer.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...